Satellos Bioscience Inc. (NASDAQ:MSLE) Receives $18.00 Consensus Price Target from Analysts

Satellos Bioscience Inc. (NASDAQ:MSLE) has been given an average recommendation of “Moderate Buy” by the six ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $18.00.

A number of equities research analysts have recently issued reports on MSLE shares. Wall Street Zen lowered Satellos Bioscience from a “sell” rating to a “strong sell” rating in a research report on Saturday, April 25th. Cantor Fitzgerald started coverage on Satellos Bioscience in a research report on Wednesday, March 11th. They issued an “overweight” rating for the company. Weiss Ratings started coverage on Satellos Bioscience in a research report on Wednesday, February 11th. They issued a “sell (d-)” rating for the company. Leerink Partners started coverage on Satellos Bioscience in a research report on Monday, April 6th. They issued an “outperform” rating and a $20.00 price target for the company. Finally, Zacks Research upgraded Satellos Bioscience to a “hold” rating in a research report on Tuesday, February 10th.

Satellos Bioscience Trading Down 4.3%

NASDAQ:MSLE opened at $8.00 on Friday. Satellos Bioscience has a 12 month low of $4.53 and a 12 month high of $13.39. The business’s 50 day moving average price is $8.26. The stock has a market cap of $166.65 million, a price-to-earnings ratio of -5.16 and a beta of 1.60.

Satellos Bioscience (NASDAQ:MSLE) last posted its quarterly earnings data on Friday, March 27th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.11). Analysts anticipate that Satellos Bioscience will post -2.04 earnings per share for the current year.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.